|Bid||104.50 x 1000|
|Ask||107.90 x 1100|
|Day's Range||104.51 - 107.93|
|52 Week Range||46.37 - 137.61|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||34.14|
|Earnings Date||Feb 18, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.57|
Emergent Biosolutions saw its IBD SmartSelect Composite Rating rise to 97 Wednesday, up from 92 the day before.
For his final "Executive Decision" segment of Monday's Mad Money program, Jim Cramer checked in Robert Kramer, President and CEO of Emergent BioSolutions , the contract manufacturer that's seen its shares plunge $40 from their August highs. EBS shares rose 1.7% Monday, however, after the company presented at the J.P. Morgan Healthcare Conference. Kramer explained that Emergent provides several different services, from devices to therapeutics to contract development to packaging for companies big and small.
Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.